Lothar Bergmann Selected Research

Viscum ribosome inactivating protein

7/2011	The preclinical and clinical activity of aviscumine: a potential anticancer drug.
8/2008	Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lothar Bergmann Research Topics

Disease

25	Renal Cell Carcinoma (Grawitz Tumor) 02/2024 - 09/2002
9	Neoplasms (Cancer) 12/2023 - 09/2002
3	Disease Progression 11/2015 - 11/2002
3	Pancreatic Neoplasms (Pancreatic Cancer) 06/2012 - 03/2009
3	Leukemia 08/2006 - 09/2002
2	Kidney Neoplasms (Kidney Cancer) 12/2023 - 08/2014
2	Hypertension (High Blood Pressure) 12/2020 - 01/2020
2	Fatigue 01/2020 - 05/2009
2	Carcinoma (Carcinomatosis) 01/2019 - 09/2002
2	Hodgkin Disease (Hodgkin's Disease) 01/2016 - 12/2012
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2016 - 04/2004
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2004 - 06/2003
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2003 - 09/2002
1	Lymphoma (Lymphomas) 11/2011
1	Carcinogenesis 06/2011
1	Exanthema (Rash) 05/2009
1	Asthenia 05/2009
1	Hypercholesterolemia 05/2009
1	Hypertriglyceridemia 05/2009
1	Mucositis 05/2009
1	Acute Promyelocytic Leukemia 08/2006
1	Philadelphia Chromosome 06/2004
1	Multiple Myeloma 10/2003
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2002
1	Melanoma (Melanoma, Malignant) 09/2002
1	Neoplasm Metastasis (Metastasis) 09/2002
1	Breast Neoplasms (Breast Cancer) 09/2002

Drug/Important Bio-Agent (IBA)

6	Sunitinib (Sutent)FDA Link 02/2024 - 01/2010
6	Everolimus FDA Link 01/2022 - 01/2013
5	temsirolimus FDA Link 01/2020 - 05/2009
4	Tyrosine Kinase InhibitorsIBA 02/2024 - 01/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2015 - 01/2013
2	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2019
2	SurvivinIBA 06/2012 - 06/2011
2	Viscum ribosome inactivating proteinIBA 07/2011 - 08/2008
2	NF-kappa B (NF-kB)IBA 06/2004 - 11/2002
1	NivolumabIBA 12/2023
1	cyclopropapyrroloindoleIBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2020
1	Proton Pump InhibitorsIBA 12/2020
1	cabozantinibIBA 01/2020
1	Brentuximab VedotinIBA 01/2016
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 12/2012
1	Glucose (Dextrose)FDA LinkGeneric 12/2012
1	8- (6- methoxypyridin- 3- yl)- 3- methyl- 1- (4- piperazin- 1- yl- 3- trifluoromethylphenyl)- 1,3- dihydroimidazo(4,5- c)quinolin- 2- oneIBA 06/2012
1	Epirubicin (Ellence)FDA LinkGeneric 11/2011
1	fludarabineIBA 11/2011
1	Rituximab (Mabthera)FDA Link 11/2011
1	Apoptosis Regulatory ProteinsIBA 06/2011
1	Small Interfering RNA (siRNA)IBA 06/2011
1	CreatinineIBA 05/2009
1	CurcuminIBA 03/2009
1	Transcription Factors (Transcription Factor)IBA 03/2009
1	mistletoe lectin IIBA 08/2008
1	ArsenicIBA 08/2006
1	Arsenic Trioxide (Trisenox)FDA Link 08/2006
1	Cytokine Receptors (Cytokine Receptor)IBA 04/2004
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2003
1	TNF Receptor-Associated Factor 1IBA 11/2002
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 11/2002
1	Messenger RNA (mRNA)IBA 09/2002
1	Hyaluronic Acid (Hyaluronan)IBA 09/2002
1	AcidsIBA 09/2002
1	AntigensIBA 09/2002

Therapy/Procedure

25	Therapeutics 12/2023 - 09/2002
4	Immunotherapy 12/2023 - 09/2002
2	Drug Therapy (Chemotherapy) 01/2016 - 08/2008
1	Transplantation 01/2016
1	Stem Cell Transplantation 01/2016
1	Duration of Therapy 04/2015